Evaluation of Target Organs Damage in Hypertensive Patients (PreVENT-A GP)

AstraZeneca

Status: Completed

Conditions: no Known Cardiovascular; Hypertensive; no Known Renal Disease; Target Organs Damage

Study type: Observational

Funder types: Industry

Identifiers

NCT01055353

NIS-CFR-DUM-2009/2

Details and patient eligibility

About

Evaluation of target organs damage in hypertensive patients with no known cardiovascular (CV) or renal disease, stratified according to level of blood pressure control

Enrollment: 1,857 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• diagnosis of essential hypertension (treated or untreated); HT not discovered on the day of the consultation; no documented clinical cardiovascular or renal disease.

Exclusion criteria